BY THE OPTIMIST DAILY EDITORIAL TEAM
In a watershed moment for women’s health, a new cervical cancer treatment regimen has been discovered to reduce the risk of death by 40 percent. Experts describe it as the greatest significant improvement in disease treatment in more than 25 years. Cervical cancer, the fourth most prevalent cancer in women worldwide, claims the lives of over 350,000 people each year. Despite advances in screening and therapy, the cancer frequently recurs, especially in women in their thirties. A decade-long study led by academics at University College London (UCL) found that a relatively simple modification to existing treatment protocols could considerably enhance survival rates.
“This is the biggest gain in survival since the adoption of chemoradiation in 1999,” stated Dr. Mary McCormack, the trial’s primary investigator at UCL. She continued: “Every improvement in survival for a cancer patient is important, especially when the treatment is well-tolerated and given for a relatively short time, allowing women to get back to their normal lives relatively quickly.”
The study: chemotherapy before chemoradiation
The novel method entails giving patients a brief course of chemotherapy before they receive chemoradiation, which is the existing standard for cervical cancer treatment. The experiment, which was called the Interlace trial, enrolled 500 women across five countries, including the UK, Mexico, India, Italy, and Brazil. Cancer Research UK funded the study, which focused on women with locally advanced cervical cancer that had not progressed to other organs.
Participants were randomly assigned to either the new combo therapy or regular chemoradiation treatment. The experimental group received carboplatin and paclitaxel treatment for six weeks before receiving the standard chemoradiation (weekly cisplatin and irradiation). The findings were startling: 80 percent of women who underwent the new program survived five years, compared to 72 percent in the control group. Furthermore, 72 percent of women in the novel treatment group saw no cancer recurrence, compared to 64 percent in the conventional therapy group.
The experiment discovered that adding this initial round of chemotherapy lowered the chance of mortality by 40 percent and the risk of cancer recurrence by 35 percent. “A short course of induction chemotherapy prior to standard chemoradiation treatment greatly boosts overall survival and reduces the risk of relapse in patients with locally advanced cervical cancer,” explained Dr. McCormack.
Hope for women with cervical cancer
Women like Abbie Halls, a 27-year-old Londoner, are already feeling the effects of the new treatment. Halls has been cancer-free for nine years since beginning the new treatment plan. “I’m not sure if I’d be here without the treatment that I received,” she shared. “I’m happy that I could play a part in advancing the research, which I hope is going to save the lives of many more women in years to come.”
Cervical cancer is a major worldwide health concern, especially in low-income countries with inadequate access to screening and treatment. Every year, there are around 660,000 new cases worldwide, and the disease kills hundreds of thousands of women. This new leadership, however, provides promise for a better future.
A call for global adoption
With such encouraging outcomes, researchers are calling for the global use of this novel therapy strategy. “It has already been adopted by some cancer centers, and there’s no reason that this shouldn’t be offered to all patients undergoing chemoradiation for this cancer,” said Dr. McCormack.
The treatment’s simplicity is one of its most positive qualities. As Dr. Iain Foulkes, executive director of research and innovation at Cancer Research UK, noted, “The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results.” He further stated that this treatment makes use of current, low-cost medications, making it more accessible to women in low-income communities.
As the fight against cervical cancer continues, this fresh approach represents a significant advancement. The combination of existing chemotherapy and radiotherapy treatments offers a practical and successful approach, with the potential to save thousands of lives and give hope to women all over the world.
Source study: The Lancet—Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
